Chilean Lab's Hantavirus Breakthrough Halted by Funds

A promising hantavirus antibody treatment developed by a Chilean lab a decade ago remains stalled due to insufficient funding. Virologist María Inés Barría recalls the breakthrough in 2016, when antibodies effectively neutralized the virus in laboratory tests. Despite successful animal trials and orphan drug status from the FDA by 2021, securing the estimated $7 million for human trials proved impossible.

The recent cluster of hantavirus infections linked to a cruise ship, which caused fatalities and illness, has spurred renewed global interest in the disease. This outbreak has highlighted the Andes strain, the only hantavirus known to transmit between people, prompting a World Health Organization alert. Researchers like Kartik Chandran are also developing vaccine and antibody treatments, with early results showing effectiveness in animal models and readiness for human trials, contingent on securing partnerships.

Hantavirus poses a significant public health challenge, particularly in Chile, which recorded 39 cases and 13 deaths in 2026, and southern Argentina. The rarity and geographical concentration of the virus historically meant it received limited attention outside affected areas. However, the cruise ship incident has amplified concerns, with passengers and crew from numerous countries potentially exposed.

While human trials are on hold, Barría's team continues to study immune responses and antibody durability, crucial for future treatment and vaccine design. The primary obstacle remains securing the substantial investment and specialized infrastructure required. Even with renewed funding, it is estimated that returning to their previous stage of development would take 12 to 24 months.